JP2018536383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536383A5 JP2018536383A5 JP2018512283A JP2018512283A JP2018536383A5 JP 2018536383 A5 JP2018536383 A5 JP 2018536383A5 JP 2018512283 A JP2018512283 A JP 2018512283A JP 2018512283 A JP2018512283 A JP 2018512283A JP 2018536383 A5 JP2018536383 A5 JP 2018536383A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cell
- variant
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021047884A JP7344919B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047883A JP7344918B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047882A JP7344917B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237091P | 2015-10-05 | 2015-10-05 | |
| GB1517538.3 | 2015-10-05 | ||
| GBGB1517538.3A GB201517538D0 (en) | 2015-10-05 | 2015-10-05 | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| US62/237,091 | 2015-10-05 | ||
| PCT/EP2016/073416 WO2017060169A1 (en) | 2015-10-05 | 2016-09-30 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021047883A Division JP7344918B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047884A Division JP7344919B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047882A Division JP7344917B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536383A JP2018536383A (ja) | 2018-12-13 |
| JP2018536383A5 true JP2018536383A5 (enExample) | 2019-06-13 |
| JP6868010B2 JP6868010B2 (ja) | 2021-05-12 |
Family
ID=54606079
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512283A Expired - Fee Related JP6868010B2 (ja) | 2015-10-05 | 2016-09-30 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047882A Active JP7344917B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047883A Active JP7344918B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047884A Active JP7344919B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021047882A Active JP7344917B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047883A Active JP7344918B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
| JP2021047884A Active JP7344919B2 (ja) | 2015-10-05 | 2021-03-22 | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US10253077B2 (enExample) |
| EP (1) | EP3359560A1 (enExample) |
| JP (4) | JP6868010B2 (enExample) |
| KR (1) | KR20180055826A (enExample) |
| CN (1) | CN108699119A (enExample) |
| AU (3) | AU2016335177B2 (enExample) |
| CA (1) | CA3001074A1 (enExample) |
| CL (1) | CL2018000780A1 (enExample) |
| CO (1) | CO2018003659A2 (enExample) |
| CR (3) | CR20200515A (enExample) |
| EA (1) | EA201890635A1 (enExample) |
| GB (1) | GB201517538D0 (enExample) |
| MA (2) | MA45424A (enExample) |
| MX (1) | MX2018004140A (enExample) |
| PE (1) | PE20181799A1 (enExample) |
| SG (2) | SG11201801344SA (enExample) |
| TW (1) | TWI776245B (enExample) |
| WO (1) | WO2017060169A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1258386A1 (zh) * | 2015-10-05 | 2019-11-08 | Immatics Biotechnologies Gmbh | 用於小细胞肺癌和其他癌症免疫治疗的肽和肽组合物 |
| GB201517538D0 (en) * | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| GB201612043D0 (en) * | 2016-07-11 | 2016-08-24 | Crescendo Biologics Ltd | Composition for treatment of disorders |
| WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| EP4316597A3 (en) | 2017-07-07 | 2024-11-06 | immatics biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers |
| US10800823B2 (en) | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| KR20200037388A (ko) * | 2017-08-16 | 2020-04-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16, 및 egfr, hla-e, ccr4 또는 pd-l1에 결합하는 단백질 |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| US11464800B2 (en) | 2018-02-09 | 2022-10-11 | Immatics US, Inc. | Methods for manufacturing T cells |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| US20210115519A1 (en) * | 2018-04-19 | 2021-04-22 | The University Of Chicago | Methods and kits for diagnosis and triage of patients with colorectal liver metastases |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| CN109485721A (zh) * | 2018-11-23 | 2019-03-19 | 杜学明 | 一种获得肿瘤特异性t细胞受体的方法 |
| US20220016271A1 (en) * | 2018-12-11 | 2022-01-20 | The Brigham And Women`S Hospital, Inc. | Methods for treating cancer |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| EP3739588A1 (en) * | 2019-05-13 | 2020-11-18 | Koninklijke Philips N.V. | Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk |
| CN110398584B (zh) * | 2019-05-23 | 2023-01-24 | 广东药科大学 | 血清Slit2作为结直肠癌诊治和转移监测标志物的应用 |
| PH12021552979A1 (en) | 2019-05-27 | 2023-10-09 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
| CN114303060A (zh) | 2019-06-06 | 2022-04-08 | 伊玛提克斯生物技术有限公司 | 使用序列相似肽进行反向选择分选 |
| AU2020301838B2 (en) * | 2019-06-25 | 2025-11-06 | Université de Montréal | Novel tumor-specific antigens for ovarian cancer and uses thereof |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| IL295891A (en) | 2020-02-24 | 2022-10-01 | Immatics Us Inc | Methods for propagating t cells for the treatment of cancer and related malignancies |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| EP4196586A1 (en) | 2020-10-08 | 2023-06-21 | Albert-Ludwigs-Universität Freiburg | Casp8ap2 antagonists for use in the prevention or treatment of cancer |
| WO2022125511A1 (en) * | 2020-12-07 | 2022-06-16 | Iogenetics, Llc | Administration of anti-tumor vaccines |
| WO2022147029A2 (en) | 2020-12-31 | 2022-07-07 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| US20250235517A1 (en) * | 2022-03-30 | 2025-07-24 | Iogenetics, Llc | Tumor-associated antigens in brain tumors |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN117384859B (zh) * | 2023-12-13 | 2024-03-22 | 北京翊博生物集团有限公司 | 一种树突状细胞来源的外泌体的制备方法及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040005561A1 (en) * | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20060045881A1 (en) * | 2004-08-26 | 2006-03-02 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| EP1760089B1 (en) | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| JP5564249B2 (ja) * | 2006-06-23 | 2014-07-30 | アレシア・バイオセラピューティクス・インコーポレーテッド | 癌に関与するポリヌクレオチド配列およびポリペプチド配列 |
| TWI538685B (zh) * | 2010-04-02 | 2016-06-21 | 腫瘤療法 科學股份有限公司 | Ｅｃｔ２胜肽及含此胜肽之疫苗 |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| ES2700514T3 (es) * | 2011-02-01 | 2019-02-18 | Genmab As | Anticuerpos humanos y conjugados de anticuerpo-fármaco contra CD74 |
| WO2012161951A1 (en) * | 2011-05-23 | 2012-11-29 | AML Therapeutics, LLC | Peptides for preventing or treating a disease or disorder associated with cbp or p300 misregulation, and methods for use and identification thereof |
| TWI714869B (zh) | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| GB201517538D0 (en) * | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
-
2015
- 2015-10-05 GB GBGB1517538.3A patent/GB201517538D0/en not_active Ceased
-
2016
- 2016-09-30 JP JP2018512283A patent/JP6868010B2/ja not_active Expired - Fee Related
- 2016-09-30 MX MX2018004140A patent/MX2018004140A/es unknown
- 2016-09-30 SG SG11201801344SA patent/SG11201801344SA/en unknown
- 2016-09-30 CR CR20200515A patent/CR20200515A/es unknown
- 2016-09-30 CN CN201680057635.2A patent/CN108699119A/zh active Pending
- 2016-09-30 PE PE2018000322A patent/PE20181799A1/es unknown
- 2016-09-30 EP EP16774689.0A patent/EP3359560A1/en active Pending
- 2016-09-30 CA CA3001074A patent/CA3001074A1/en active Pending
- 2016-09-30 EA EA201890635A patent/EA201890635A1/ru unknown
- 2016-09-30 SG SG10202003124TA patent/SG10202003124TA/en unknown
- 2016-09-30 US US15/281,537 patent/US10253077B2/en active Active
- 2016-09-30 AU AU2016335177A patent/AU2016335177B2/en not_active Ceased
- 2016-09-30 MA MA045424A patent/MA45424A/fr unknown
- 2016-09-30 MA MA42021A patent/MA42021A1/fr unknown
- 2016-09-30 CR CR20200516A patent/CR20200516A/es unknown
- 2016-09-30 CR CR20180191A patent/CR20180191A/es unknown
- 2016-09-30 KR KR1020187007972A patent/KR20180055826A/ko not_active Ceased
- 2016-09-30 WO PCT/EP2016/073416 patent/WO2017060169A1/en not_active Ceased
- 2016-10-05 TW TW109133819A patent/TWI776245B/zh not_active IP Right Cessation
-
2018
- 2018-03-26 CL CL2018000780A patent/CL2018000780A1/es unknown
- 2018-04-05 CO CONC2018/0003659A patent/CO2018003659A2/es unknown
- 2018-12-27 US US16/233,284 patent/US10377802B2/en active Active
- 2018-12-31 US US16/237,284 patent/US10597432B2/en active Active
- 2018-12-31 US US16/237,279 patent/US10487126B2/en active Active
-
2019
- 2019-10-02 US US16/591,323 patent/US10654904B2/en not_active Expired - Fee Related
-
2021
- 2021-02-19 AU AU2021201107A patent/AU2021201107A1/en not_active Abandoned
- 2021-02-19 AU AU2021201108A patent/AU2021201108A1/en not_active Abandoned
- 2021-03-22 JP JP2021047882A patent/JP7344917B2/ja active Active
- 2021-03-22 JP JP2021047883A patent/JP7344918B2/ja active Active
- 2021-03-22 JP JP2021047884A patent/JP7344919B2/ja active Active